Navigation
Company
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Contact Us
General Contact
For Healthcare Professionals
Careers
Archive: April, 2024
Home
2024
April
11
Apr
2024
Evaluation of
nab
-sirolimus in combination with fulvestrant or PI3K pathway inhibitors to overcome resistance in breast cancer cell lines
0
0
April 11, 2024
Evaluation of nab-sirolimus in combination with fulvestrant or PI3K pathway inhibitors to overcome resistance in breast cancer cell lines
April 11, 2024
09
Apr
2024
Correlation of
nab
-sirolimus tumor drug levels and improved tumor suppression in
KRAS G12C
non-small cell lung cancer xenografts treated with
nab
-sirolimus in combination with KRAS inhibitors
0
0
April 9, 2024
Correlation of nab-sirolimus tumor drug levels and improved tumor suppression in KRAS G12C non-small cell lung cancer xenografts treated with nab-sirolimus in combination with KRAS inhibitors
April 9, 2024
